Platelet growth factors and indications currently under investigation.
| Romiplostim (AMG531) |
| Thrombopoietin (TPO) peptide mimetic |
| Binds at the endogenous TPO-binding site |
| Weekly subcutaneous administration |
| Eltrombopag (Promacta, SB49711) |
| TPO non-peptide mimetic |
| Binds at the intramembrane portion of the TPO receptor |
| Daily oral administration |
| AKR-501 (YM 477) |
| TPO non-peptide mimetic |
| Binding remote from endogenous TPO-binding site |
| Daily oral administration |
| Indications currently under investigation |
| Autoimmune thrombocytopenia |
| Thrombocytopenia associated with chronic liver disease |
| Thrombocytopenia associated with the treatment of hepatitis C virus |
| Thrombocytopenia induced by chemotherapy for malignancy |
| Thrombocytopenia associated with intrinsic marrow abnormalities |
| Thrombocytopenia associated with the treatment of hematologic malignancy |
| Romiplostim (AMG531) |
| Thrombopoietin (TPO) peptide mimetic |
| Binds at the endogenous TPO-binding site |
| Weekly subcutaneous administration |
| Eltrombopag (Promacta, SB49711) |
| TPO non-peptide mimetic |
| Binds at the intramembrane portion of the TPO receptor |
| Daily oral administration |
| AKR-501 (YM 477) |
| TPO non-peptide mimetic |
| Binding remote from endogenous TPO-binding site |
| Daily oral administration |
| Indications currently under investigation |
| Autoimmune thrombocytopenia |
| Thrombocytopenia associated with chronic liver disease |
| Thrombocytopenia associated with the treatment of hepatitis C virus |
| Thrombocytopenia induced by chemotherapy for malignancy |
| Thrombocytopenia associated with intrinsic marrow abnormalities |
| Thrombocytopenia associated with the treatment of hematologic malignancy |